INTERIM REPORT 1 JULY– 30 SEPTEMBER 2018
“We are concluding yet another intense quarter for Episurf Medical. We are continuing to deliver on our strategy, and the activity level is high across our business. We are approaching the completion of two of our most important milestones ever, namely the approval to start a clinical trial in the US and the launch of an individualised ankle implant. We are improving our results during the quarter, driven both by increased revenues and lowered operating expenses", says Pål Ryfors, CEO Episurf Medical.
Third quarter 2018 compared to 2017, Group
» Group net sales increased by 86.7% compared to last year and amounted to SEK 1.0m (0.5)
» Gross order intake amounted to SEK 0.7m (0.9), a decrease of 15.5%. The number of approved orders amounted to 35 (42)
» Order backlog amounted to SEK 0.6m (0.8)
» Loss before tax amounted to SEK –12.9m (–13.5)
» Earnings per share amounted to SEK –0.42 (–0.44)
Significant events during the third quarter
» Episurf Medical released new CE-marked joint visualisation tool based on Al
» Episurf Medical has received initial feedback from the US FDA on the IDE application for the Episealer® knee Implant
» Episurf Medical expanded into the Polish Market
» Promising clinical results from use of Episealer® was accepted for presentation at the annual meeting of the Australian Knee Society in October
» Clinical outcome for Episealer® was presented at the annual meeting of the European Orthopaedic Research Society (EORS) In Galway, Irland In September
» Patent approvals in Japan, US, Canada and Australia for Episurf Medical
Significant events after the third quarter
» Clinical outcome for Episealer® to be presented at the annual meeting of the Danish Orthoaedic Society (DOS) In Copenhagen in October
» New Chinese patent approval for Episurf Medical
För mer information, vänligen kontakta:
Pål Ryfors, vd, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Veronica Wallin, cfo, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com
Om Episurf Medical
Episurf Medical arbetar för att erbjuda människor med smärtsamma ledskador ett aktivare och friskare liv genom att tillgängliggöra minimalt invasiva samt skräddarsydda behandlingsalternativ. Episurf Medicals individanpassade implantat Episealer® och kirurgiska instrument Epiguide® används för behandling av lokala broskskador i leder. Med Episurf Medicals μiFidelity®-system anpassas implantaten kostnadseffektivt till respektive persons unika skada för optimal passform och minimalt ingrepp. Episurf Medical har huvudkontor i Stockholm, Sverige. Aktien (EPIS B) är noterad på Nasdaq Stockholm. Mer information finns på bolagets hemsida: www.episurf.com.
Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande kl. 08.30 den 26 October 2018.
Tags: